RxDoctor Payments Data

Clifford Gladstone, MD

Cardiovascular Disease · Somerset, NJNPI 1548266265

Payments from drug & device makers

$47in general payments, 2019–2025

Across 3 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$47

What the payments were for

  • Food & beverage$47100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis3$47

How this compares

$47 in reported general payments places this provider in the 5th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$433,617
Medicare patients
1,057
Services billed
3,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$264,570
EntrestoSacubitril/Valsartan56$89,686
XareltoRivaroxaban27$41,813
Repatha SureclickEvolocumab17$27,927
Praluent PenAlirocumab15$19,699
MultaqDronedarone Hcl17$19,532
Metoprolol Succinate429$6,996
Atorvastatin Calcium417$4,319
Ranolazine ErRanolazine28$3,619
Candesartan Cilexetil22$2,322
Rosuvastatin Calcium131$2,320
Ezetimibe50$2,171
Amlodipine Besylate322$2,121
Valsartan65$2,060
Losartan Potassium165$2,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$47$89,68656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Somerset

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →